Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (7371)	12/27/1999 3:26:00 PM
From: Vector1	Respond to of 9719

Someone has lit a fire under CLTR. This could be our biggest day yet. V1

To: Vector1 who wrote (7371)	12/27/1999 3:51:00 PM
From: bluejeans	Read Replies (1) \| Respond to of 9719

Or buy a put from this list: quote.cboe.com

To: Vector1 who wrote (7371)	12/27/1999 5:26:00 PM
From: LLCF	Respond to of 9719

<Someone please talk me out of selling 500 shares of INCY> Nope, put a collar on 25% of my position today as a matter of fact. DAK

To: Vector1 who wrote (7371)	12/27/1999 11:56:00 PM
From: RCMac	Read Replies (1) \| Respond to of 9719

>> Someone please talk me out of selling 500 shares of INCY . . . at 63 << V1, let me try. See Larry Liebman's posts this evening on the Biotech Valuation thread: Message 12392981 Message 12393217 and Message 12393590 And Peter Suzman's: Message 12393635 It is far from clear that the momentum in the genomics stocks will let up soon, even though it has taken INCY to more than we might think of as “fair value.” (Although mostly I'm just puzzled about what fair value might be – I don't have a clear idea what INCY's arguable advantage in software, partnerships and patent applications, and its contract rights to royalties on drugs developed with its databases and reagents, are “worth” – probably a potentially humungous amount, but that depends on how a lot of things work out, that we won't know for a while. Since the price of Venter's CRA has benefited from far more hype than INCY, which notably goes unmentioned in many articles about the genomics companies, INCY is likely less far “ahead of itself” than CRA, HGSI, and the rest). Although I lightened up a bit Thursday in INCY (some IRA shares, some long-term capital gain shares), I sort of wish I hadn't, and expect to stand pat with the remaining 80% of my position and see how far this thing can roar. --RCM